Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/2010
02/04/2010WO2010014888A2 Methods of enhancing opsonophagocytosis in response to a pathogen
02/04/2010WO2010014830A2 Peptide therapeutics that bind vegf and methods of use thereof
02/04/2010WO2010014746A1 Materials and methods for treatment of spinal muscular atrophy and taxane-induced peripheral neuropathy (tipn)
02/04/2010WO2010014629A1 Multi-specific binding proteins targeting b cell disorders
02/04/2010WO2010014616A2 Prominin-1 peptide fragments and uses thereof
02/04/2010WO2010014541A2 Compositions and methods for treatment of hypercholesterolemia
02/04/2010WO2010014250A1 Prediction of cancer therapy based on cathespin b levels
02/04/2010WO2010014249A1 Cancer therapy comprising estrogen inhibitors
02/04/2010WO2010014248A2 Antiviral activity of the protein scytovirin and methods of use
02/04/2010WO2010014176A2 Preparation method of biodegradable micro-particles containing drugs
02/04/2010WO2010014130A1 Composition and method to prevent or reduce diarrhea and steatorrhea in hiv patients
02/04/2010WO2010014000A1 Susceptibility markers for multiple sclerosis
02/04/2010WO2010013495A1 Pharmaceutical composition containing highly purified botulinum neurotoxin therapeutic agent as active ingredient, and use thereof
02/04/2010WO2010013494A1 Pharmaceutical composition comprising botulinum neurotoxin preparation incapable of being synaptically transported, and use thereof
02/04/2010WO2010013485A1 Melk epitope peptides and vaccines containing the same
02/04/2010WO2010013231A2 Modulation of coagulation factors and effectors of same for control of transplant organ size
02/04/2010WO2010013204A1 Composition for regenerating senescent cutaneous and sub-cutaneous tissue, products and uses thereof
02/04/2010WO2010013191A2 Cosmetic composition and process for regrowth of integumentary system
02/04/2010WO2010012912A2 Use of a soluble form of hla-g in the treatment of abnormal b-lymphocyte proliferation
02/04/2010WO2010012749A1 Immunotherapy compositions for the treatment and prevention of amyloidosis
02/04/2010WO2010012438A2 Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor
02/04/2010WO2010012088A1 Apparatus and method for loading and transporting containers
02/04/2010WO2010012073A1 Nonimmunosuppressive cyclosporine analogue molecules
02/04/2010WO2009150371A3 Nanoparticles containing a peptide, vectors containing the same and pharmaceutical uses of said nanoparticles and said vectors
02/04/2010WO2009148954A3 Tpo mimetic peptide for preventing hematological disorder associated with cancer treatment
02/04/2010WO2009148583A3 Method for improvement of octreotide bioavailability
02/04/2010WO2009135135A3 Fibromodulin formulation for reducing corneal scarring
02/04/2010WO2009108760A8 Dendritic macroporous hydrogels prepared by crystal templating
02/04/2010WO2009090227A3 PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN α1 LOOP 2 OR β2 LOOP 1 OF AN ADRENORECEPTOR
02/04/2010WO2009062050A9 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
02/04/2010WO2009019260A3 Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage
02/04/2010WO2009003283A8 Novel compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same
02/04/2010US20100031396 and processing of transgenic sugarcane using a nucleic acid encoding the promoter of a Sugarcane Elongation Factor (SEF)
02/04/2010US20100030543 Products and processes for modulating peptide-peptide binding domain interactions
02/04/2010US20100029922 Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes
02/04/2010US20100029751 Compositions comprising a parvovirus vp1-variant and a parvovirus ns1 protein for induction of cytolysis
02/04/2010US20100029747 Methods and compositions for inhibiting the function of polynucleotide sequences
02/04/2010US20100029712 Irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
02/04/2010US20100029575 N-Oxides of Kappa Receptor Peptides
02/04/2010US20100029574 Cosmetic compositions
02/04/2010US20100029573 Tumor-associated peptides that bind to mhc-molecules
02/04/2010US20100029572 Neurotrophic Peptides
02/04/2010US20100029571 Novel and powerful mhc-class ii peptides derived from survivin
02/04/2010US20100029570 Peptide and treatment for hiv-1 infection
02/04/2010US20100029569 Pharmaceutical Formulation
02/04/2010US20100029568 Tighter-binding c-peptide inhibitors of hiv-1 entry
02/04/2010US20100029567 Method of correcting imbalance between bone resorption and bone formation and kits and compositions therefor
02/04/2010US20100029566 Use of at least one botulinum neurotoxin for treating the pain induced by therapeutic treatments for the aids virus
02/04/2010US20100029565 RECOMBINANT B. pseudomallei ADHESIN PROTEIN AND METHODS AND USES THEREOF
02/04/2010US20100029564 Novel process of solubilizing protein from a proteinaceous material and compositions thereof
02/04/2010US20100029563 administering a composition comprising a GM-CSF cysteine mutein of SEQ ID NO:8, wherein a cysteine residue is substituted for an amino acid selected from the group consisting of A1, A3, S5, S7, N27, T32, A33, E51, R67, S69, E93, T94, T98, Q99, T102, E123, V125, Q126, and E127
02/04/2010US20100029562 hG31P Expression System
02/04/2010US20100029561 Ameliorating agent for insulin resistance
02/04/2010US20100029560 Compositions and methods for diagnosing, treating, and preventing prostate conditions
02/04/2010US20100029559 Method for achieving desired glial growth factor 2 plasma levels
02/04/2010US20100029558 Alpha1 proteinase inhibitor peptides methods and use
02/04/2010US20100029557 Alpha-lactalbumin composition
02/04/2010US20100029556 Stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof
02/04/2010US20100029555 G-csf site-specific mono-conjugates
02/04/2010US20100029554 Composition and Methods for Treatment of Congestive Heart Failure
02/04/2010US20100029553 Microfluidic Device for Controlled Aggregation of Spider Silk
02/04/2010US20100029552 Peptide inhibitors of c-jun dimerization and uses thereof
02/04/2010US20100029551 Treatment Of Inflammatory Lung Conditions With Aerosolized Macrolide Antibiotics
02/04/2010US20100029550 Organic compounds
02/04/2010US20100029549 Situ self-setting mineral-polymer hybrid materials, composition and use thereof
02/04/2010US20100029548 Glycoproteins produced in plants and methods of their use
02/04/2010US20100029547 Mvl, an antiviral protein from a cyanobacterium
02/04/2010US20100029546 preparation method of galactosyl-has magnetic nanoparticles containing adriamycin
02/04/2010US20100029545 Boronic acid-containing block copolymers for controlled drug delivery
02/04/2010US20100029544 Composition
02/04/2010US20100029543 Using peptides such as lacosamide to treat pain induced by an antitumor nucleoside analogue or an antiviral nucleoside analogue
02/04/2010US20100029542 Protein sterilisation by radiation and addition of a stabilising composition
02/04/2010US20100028995 Tetranectin Trimerizing Polypeptides
02/04/2010US20100028910 Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
02/04/2010US20100028905 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
02/04/2010US20100028485 Talaromyces emersonii enzyme systems
02/04/2010US20100028454 Preparation method for biodegradable micro-particles containing drugs
02/04/2010US20100028451 Silk microspheres for encapsulation and controlled release
02/04/2010US20100028446 Transport of drugs via the blood-brain barrier by means of apolipoproteins
02/04/2010US20100028431 Compositions and methods for therapeutic use
02/04/2010US20100028430 Material and manufacturing method of bioactive protein-calcium phosphate composite
02/04/2010US20100028424 Multilayer thin film comprising two or more adjacent layers of oppositely charged polyelectrolytes and encapsulated antigenic peptides; vaccine development for hepatitis B virus, HIV, bacteria, parasites, and viruses
02/04/2010US20100028421 Solid Oral Dosage Form Containing an Enhancer
02/04/2010US20100028420 Controlled release composition and process
02/04/2010US20100028412 Transdermal therapeutic system for administering water-soluable active ingredients
02/04/2010US20100028404 Compound and device for treating bone and/or cartilage defects
02/04/2010US20100028401 Stem cell source for promoting neovascularisation
02/04/2010US20100028396 Tissue scaffolds derived from forestomach extracellular matrix
02/04/2010US20100028387 Biocompatible Coated Nanostructured Titanium Surfaces
02/04/2010US20100028378 Toxin-antitoxin system and applications thereof
02/04/2010US20100028375 Vlp based vaccine delivery system
02/04/2010US20100028374 C-type lectin transmembrane antigen expressed in human prostate cancer and uses therof
02/04/2010US20100028373 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
02/04/2010US20100028370 Megalin-based delivery of therapeutic compounds to the brain and other tissues
02/04/2010US20100028366 Synergistic effect between a cyanogenic system and another oxidative inducing system for treating tumors
02/04/2010US20100028360 Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases
02/04/2010US20100028353 Anti-amyloid immunogenic compositions, methods and uses
02/04/2010US20100028352 COMPOSITIONS AND METHODS COMPRISING GLYCYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
02/04/2010US20100028349 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity
02/04/2010US20100028344 Conditioned cell immunization
1 ... 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 ... 3163